New drug combo aims to outsmart resistant lung cancer
Disease control
Not yet recruiting
This Phase II trial tests a combination of two drugs, JS212 and JS111, in about 35 people with advanced non-small cell lung cancer that has a specific EGFR mutation and has stopped responding to prior treatment. The study will first find the safest dose, then check how well the c…
Phase: PHASE2 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC